Dr. Max Temnik, PhD
Founder
Welcome to ZNA Bio, a Metallomix Company
We are a clinical-stage biotech driven to create significant medicines for people suffering from debilitating, life-threatening diseases. With that mission in mind, we live and work to explore our proprietary research of isotopic signatures in cells and tissues, and to develop a pipeline of novel medicines that may help people in need of a meaningful, desease-modifying medicine.
Our Innovation
We are leading the development of principally new isotope-selective modulation (ISM) class of therapies designed to activate disease-modifying mechanisms that slow-down, stop, and eradicate cancer.
Our Science
Our distinctive scientific approach is rooted in over ten years of research in metalloproteomics that delves beyond molecular patterns, and explores isotopic signatures within biological cells and tissues at the atomic level.
Our Mission
We live and work to become a world-leading metallogenomic pharmaceutical company developing clinically de-risked, inherently safe and effective disease-modifying drugs for oncological diseases
Our Capabilities
Our first-in-class drug candidate have shown ability to Increase wild-type p53 levels and induce T-cell activity while reducing local and systemic inflammation without suppressing the immune system or harming healthy cells
Making The Difference
At the intersection of metallomics and drug development, ZNA Bio pioneers with an innovative isotope-selective modulation (ISM) class of therapy, which targets isotopic fractionation in cells and tissues as previously unrecognized driver of many diseases. Our over a decade-long research, preclinical results, and initial clinical data provide strong scientific rationale for the development of inherently safe and clinically significant medicines that may assist in reducing cancer resistance to several drugs, slowing down the development of obesity and fat liver diseases, and alleviating the suffering associated with Parkinson's and Alzheimer's diseases, lupus, and several other diseases
A Multi-Omic Approach
Metallomics integrates chemistry, biology, physics, and medicine focusing on the roles of metals in biological systems. It examines the metallome - the full spectrum of metals withing cells and organisms - using advanced mass spectrometry to uncover metal concentrations, distributions, and interactions. Metallome is crucial for understanding diseases linked to metal imbalances, such as cancer and neurodegenerative disorders, and for exploring the fundamental processes of life. Unlike conventional medications that typically interact with their targets on a surface level, thereby managing symptoms rather than the root cause, our isotope-selective modulators use a multi-omic approach, which empowers us to create novel pharmaceuticals that modulate critical biological pathways, ranging from protein synthesis to vital cellular functions and DNA repair.
The Next Evolutionary Step in Developing Advanced Medicines
The insights from metallomics are revolutionizing drug discovery by identifying new therapeutic targets and improving drug delivery. Metallomics also supports the development of precision medicines by tailoring treatments to metallomic profiles, enhancing drug delivery and safety. We believe that the exploration of metal isotopes for targeted therapies further amplifies the innovative applications of metallomics in creating more precise and less toxic drugs, and promises to be a key driver in the development of advanced medical treatments. The inherent safety profile of stable light isotopes highlights its transformative potential in the pharmaceutical industry, promising a new era of treatments that are both more effective and clinically safe.
Our Firm Commitment
To Our Patients
We are committed to developing novel, disease-modifying therapies dedicated to saving and improving your lives. We know time matters.
To Our Colleagues
We are committed to challenge you and ourselves in order to find the out-of-the-box, sustainable solutions while ensuring quality and safety of our products..
To Our Partners
We are committed to integrity and transparency, and to discovering and developing therapies in a diligent manner by using reliable data and critical thinking..
Our Leadership
Led by our founders and their experience in creating successful companies, we are assembling the team of industry-tempered and purpose-driven specialty professionals who improve our innovative stance and share our passion for working towards helping others. With focus on creating value, we endorse lean enterprise principles and seek strategic partnerships, while outsourcing capital-intensive research capabilities to reputable third-parties. We continually seek and evaluate wide spectrum of operating resources that may enable our growth and empower our business.
Our Drug Development Platform
Our proprietary isotope-selective modulation therapy is a new class of targeted immunotherapy that is poised to improve the treatment of several oncological malignancies. Based on our analysis of isotopic signatures in biological cells and tissues and our deep drug discovery, we seek to create novel precision medicines against more than a half of life-threatening oncological malignancies. By tying non-radioactive ("cold") isotopes into small molecules, these potent therapies can selectively improve vital physiological processes and restore cellular homeostasis throughout the body. We seek to create the medicines that enable us to help physicians bringing a smile of relief, closer to the day they can say to their patients "You are cured."